Cargando…

VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer patients

BACKGROUND: Peritoneal dissemination and retroperitoneal lymph node involvement are main routes for progression of epithelial ovarian cancer (EOC). Vascular endothelial growth factor (VEGF) mediated angiogenesis has been identified as an important mechanism promoting tumour progression. METHODS: Tum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kuerti, Sascha, Oliveira-Ferrer, Leticia, Milde-Langosch, Karin, Schmalfeldt, Barbara, Legler, Karen, Woelber, Linn, Prieske, Katharina, Mahner, Sven, Trillsch, Fabian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5522140/ https://www.ncbi.nlm.nih.gov/pubmed/28591727 http://dx.doi.org/10.18632/oncotarget.17978

Ejemplares similares

VEGF-C serum level is associated with response to bevacizumab maintenance therapy in primary ovarian cancer patients
por: Ding, Yi, et al.
Publicado: (2022)

E-Cadherin fragments as potential mediators for peritoneal metastasis in advanced epithelial ovarian cancer
por: Trillsch, Fabian, et al.
Publicado: (2016)

Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer
por: Prieske, Katharina, et al.
Publicado: (2017)

TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients
por: Mahner, Sven, et al.
Publicado: (2010)

Ang-2 is a potential molecular marker for lymphatic metastasis and better response to bevacizumab therapy in ovarian cancer
por: Volk, Annabelle, et al.
Publicado: (2023)

Targeted Therapeutic Approaches in Vulvar Squamous Cell Cancer (VSCC): Case Series and Review of the Literature
por: Woelber, Linn, et al.
Publicado: (2021)

Beyond Bevacizumab: An Outlook to New Anti-Angiogenics for the Treatment of Ovarian Cancer
por: Mahner, Sven, et al.
Publicado: (2015)

Mechanisms of Tumor-Lymphatic Interactions in Invasive Breast and Prostate Carcinoma
por: Oliveira-Ferrer, Leticia, et al.
Publicado: (2020)

Prognostic Impact of CEACAM1 in Node-Negative Ovarian Cancer Patients
por: Oliveira-Ferrer, Leticia, et al.
Publicado: (2018)

Pelvic lymphadenectomy in vulvar cancer and its impact on prognosis and outcome
por: Jaeger, A., et al.
Publicado: (2021)

Prognostic relevance of the Golgi mannosidase MAN1A1 in ovarian cancer: impact of N-glycosylation on tumour cell aggregation
por: Hamester, Fabienne, et al.
Publicado: (2019)

BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer
por: Elazezy, Maha, et al.
Publicado: (2021)

Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients
por: Meng, Xiaodan, et al.
Publicado: (2015)

Reduced mannosidase MAN1A1 expression leads to aberrant N-glycosylation and impaired survival in breast cancer
por: Legler, Karen, et al.
Publicado: (2018)

Relevance of activated leukocyte cell adhesion molecule (ALCAM) in tumor tissue and sera of cervical cancer patients
por: Ihnen, Maike, et al.
Publicado: (2012)

Comparison of PapilloCheck and Linear Array to Detect and Differentiate Human Papillomaviruses in Cervical and Tonsillar Smears from Females with Cervical Intraepithelial Lesions
por: Grimm, Donata, et al.
Publicado: (2018)

Diagnostic and prognostic relevance of circulating exosomal miR-373, miR-200a, miR-200b and miR-200c in patients with epithelial ovarian cancer
por: Meng, Xiaodan, et al.
Publicado: (2016)

Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer
por: Woelber, Linn, et al.
Publicado: (2011)

Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (BOT)
por: Trillsch, Fabian, et al.
Publicado: (2013)

Transcriptome Analysis in Vulvar Squamous Cell Cancer
por: Prieske, Katharina, et al.
Publicado: (2021)

The role of the desmosomal protein desmocollin 2 in tumour progression in triple negative breast cancer patients
por: Reimer, Francesca, et al.
Publicado: (2023)

A Systematic Model Specification Procedure for an Illness-Death Model without Recovery
por: Eulenburg, Christine, et al.
Publicado: (2015)

Combined Liquid Biopsy Methylation Analysis of CADM1 and MAL in Cervical Cancer Patients
por: Leffers, Markus, et al.
Publicado: (2022)

Diagnostic workup for endometrioid borderline ovarian tumors (eBOT) requires histopathological evaluation of the uterus
por: Reichenbach, Juliane, et al.
Publicado: (2021)

Insights into the Steps of Breast Cancer–Brain Metastases Development: Tumor Cell Interactions with the Blood–Brain Barrier
por: Hamester, Fabienne, et al.
Publicado: (2022)

C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma
por: Mahner, S, et al.
Publicado: (2008)

Key Role of Hyaluronan Metabolism for the Development of Brain Metastases in Triple-Negative Breast Cancer
por: Hamester, Fabienne, et al.
Publicado: (2022)

Protocol to optimize the biobanking of ovarian cancer organoids by accommodating patient-specific differences in stemness potential
por: Trillsch, Fabian, et al.
Publicado: (2023)

Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium
por: Trillsch, Fabian, et al.
Publicado: (2013)

Changes in Stem Cell Regulation and Epithelial Organisation during Carcinogenesis and Disease Progression in Gynaecological Malignancies
por: Cunnea, Paula, et al.
Publicado: (2021)

Asbestos Exposure and Ovarian Cancer – a Gynaecological Occupational Disease. Background, Mandatory Notification, Practical Approach
por: Nowak, Dennis, et al.
Publicado: (2021)

Clinical Relevance of Loss of 11p15 in Primary and Metastatic Breast Cancer: Association with Loss of PRKCDBP Expression in Brain Metastases
por: Wikman, Harriet, et al.
Publicado: (2012)

Molecular characteristics and tumorigenicity of ascites‐derived tumor cells: mitochondrial oxidative phosphorylation as a novel therapy target in ovarian cancer
por: Ding, Yi, et al.
Publicado: (2021)

Impact of Introducing a PACU24 Concept on the Perioperative Outcome of Patients with Advanced Ovarian Cancer Treated with Cytoreductive Surgery
por: Reuter, Susanne, et al.
Publicado: (2023)

c-FOS suppresses ovarian cancer progression by changing adhesion
por: Oliveira-Ferrer, L, et al.
Publicado: (2014)

Role of Pelvic Lymph Node Resection in Vulvar Squamous Cell Cancer: A Subset Analysis of the AGO-CaRE-1 Study
por: Woelber, Linn, et al.
Publicado: (2021)

Changes in gynecologic and breast cancer diagnoses during the first wave of the COVID-19 pandemic: analysis from a tertiary academic gyneco-oncological center in Germany
por: Kaltofen, Till, et al.
Publicado: (2021)

Demand for integrative medicine among women with breast and gynecological cancer: a multicenter cross-sectional study in Southern and Northern Germany
por: Grimm, Donata, et al.
Publicado: (2020)

The impact of Enhanced Recovery after Surgery (ERAS) pathways with regard to perioperative outcome in patients with ovarian cancer
por: Reuter, Susanne, et al.
Publicado: (2021)

Propensity Scoring after Multiple Imputation in a Retrospective Study on Adjuvant Radiation Therapy in Lymph-Node Positive Vulvar Cancer
por: Eulenburg, Christine, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3oel4ps0j9hfffuqehabqebv47